COMPLEMENT INHIBITOR ECULIZUMAB IN ATYPICAL HEMOLYTIC-UREMIC SYNDROME: SINGLE CENTER CASE SERIES

Monika Vitkauskaitė¹, Artūras Vinikovas¹, Marius Miglinas¹, Laurynas Rimševičius¹, Agnė Čerkauskaitė¹, Ernesta Mačionienė¹, and Eglė Ašakienė¹

¹Vilniaus universitetas Medicinos fakultetas

October 4, 2021

Abstract

Our case series showed that eculizumab is efficacious and safe in treating atypical hemolytic-uremic syndrome, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Hosted file

Main_text.docx available at <https://authorea.com/users/439437/articles/540379-complement-inhibitor-eculizumab-in-atypical-hemolytic-uremic-syndrome-single-center-case-series>